FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215767230> ?p ?o ?g. }

• W3215767230 endingPage "4685" @default.
• W3215767230 startingPage "4685" @default.
• W3215767230 abstract "Abstract Background: Although clinical trial data exist describing the adverse effects of Bruton's tyrosine kinase inhibitors (BTKi)s, the patient experience outside clinical trials, including differences among agents is less well-described. We evaluated the selection criteria, efficacy and toxicities related to the use of BTKi at our site. Methods: A retrospective patient chart review was used to collect data from patients treated with one or more BTKi. Demographics, prior therapies, duration of treatment, response to treatment, and incidence and severity of pre-determined toxicities of interest were collected for each patient. Descriptive statistics for each variable were reported. Association between variables of interest and the study cohort were examined using ANOVA for categorical variables and Pearson correlation coefficient for continuous variables. Survival and duration of treatment were estimated using the Kaplan-Meier method according to first novel agent. Survival analysis for each novel agent was conducted using Cox proportional hazards models and log-rank tests. Results: One hundred forty patients were included in this study, including 94 patients with CLL, 24 with MCL, and 22 with other NHL subtypes. One hundred thirteen patients received ibrutinib, while 17 patients received acalabrutinib (n=16) or zanubrutinib (n=1), which were combined in the statistical analysis. Of patients receiving ibrutinib, 69% reported at least one toxicity event during the duration of their treatment. Across all patients who received ibrutinib, 35 individuals did not report a toxicity, 48 individuals reported one toxicity, and 30 individuals reported two or more toxicities. Among the 78 patients who experienced at least one toxicity, 41 (52.5%) discontinued the medication due to these adverse effects, most commonly cytopenias (n=9), diarrhea (n=8), and fatigue (n=9). 57% of patients who reported diarrhea, 36% of patients who reported cytopenias, and 33% of patients who reported fatigue discontinued therapy due to that reported AE. In total, 60/113 patients receiving ibrutinib discontinued therapy, including 40 (66%) due to toxicity and 14 (23.3%) due to disease progression. The remaining patients discontinued therapy due to voluntary choice of new therapy or due to personal decision to stop treatment. Patients remained on ibrutinib therapy for a median duration of 40 months. 53% of patients taking zanabrutinib or acalabrutinib reported at least 1 toxicity, but only 11.7% of patients discontinued therapy for any reason. All patients who discontinued zanubrutinib/acalabrutinib therapy did so due to toxicity, with no patients ceasing therapy due to disease progression. Because only 2 of 17 patients discontinued zanubrutinib/acalabrutinib treatment, a raw median duration of treatment was calculated to be 5 months. 12.4% of patients taking ibrutinib experienced a gastrointestinal toxicity, whereas 5.9% of patients taking acalabrutinib/zanubrutinib experienced a gastrointestinal toxicity (Table 1). Additionally, 8% of individuals taking ibrutinib reported a musculoskeletal toxicity, while no acalabrutinib/zanubrutinib patients reported a musculoskeletal toxicity. There were no statistically significant differences in frequency of toxicities encountered, possibly due to study size. Other toxicities common to all analyzed BTK inhibitors included hematological, cardiovascular, and constitutional adverse effects with no significant difference between agents. Conclusions: We identified that &gt;1/3 of individuals taking BTK inhibitors are stopping therapy prematurely due to toxicity related outcomes rather than due to disease progression. Our findings suggest that proactive identification and management of adverse effects could prolong therapy duration and provide better outcomes for patients. Strategies to personalize therapy selection to limit therapy discontinuation due to toxicity are needed as additional targeted agents are developed. Figure 1 Figure 1. Disclosures Valla: BeiGene: Speakers Bureau. Cohen: Janssen, Adaptive, Aptitude Health, BeiGene, Cellectar, Adicet, Loxo/Lilly, AStra ZenecaKite/Gilead: Consultancy; Genentech, Takeda, BMS/Celgene, BioInvent, LAM, Astra Zeneca, Novartis, Loxo/Lilly: Research Funding." @default.
• W3215767230 created "2021-12-06" @default.
• W3215767230 creator A5007477825 @default.
• W3215767230 creator A5038794860 @default.
• W3215767230 creator A5042689752 @default.
• W3215767230 creator A5043541884 @default.
• W3215767230 creator A5045963130 @default.
• W3215767230 date "2021-11-05" @default.
• W3215767230 modified "2023-09-27" @default.
• W3215767230 title "Discontinuation Due to Toxicity Limits Treatment Duration of BTK Inhibitors in Non-Hodgkin Lymphoma" @default.
• W3215767230 doi "https://doi.org/10.1182/blood-2021-151791" @default.
• W3215767230 hasPublicationYear "2021" @default.
• W3215767230 type Work @default.
• W3215767230 sameAs 3215767230 @default.
• W3215767230 citedByCount "0" @default.
• W3215767230 crossrefType "journal-article" @default.
• W3215767230 hasAuthorship W3215767230A5007477825 @default.
• W3215767230 hasAuthorship W3215767230A5038794860 @default.
• W3215767230 hasAuthorship W3215767230A5042689752 @default.
• W3215767230 hasAuthorship W3215767230A5043541884 @default.
• W3215767230 hasAuthorship W3215767230A5045963130 @default.
• W3215767230 hasBestOaLocation W32157672301 @default.
• W3215767230 hasConcept C10515644 @default.
• W3215767230 hasConcept C126322002 @default.
• W3215767230 hasConcept C143998085 @default.
• W3215767230 hasConcept C197934379 @default.
• W3215767230 hasConcept C2777938653 @default.
• W3215767230 hasConcept C2778461978 @default.
• W3215767230 hasConcept C2778715236 @default.
• W3215767230 hasConcept C2779878957 @default.
• W3215767230 hasConcept C29730261 @default.
• W3215767230 hasConcept C50382708 @default.
• W3215767230 hasConcept C66339696 @default.
• W3215767230 hasConcept C71924100 @default.
• W3215767230 hasConcept C72563966 @default.
• W3215767230 hasConceptScore W3215767230C10515644 @default.
• W3215767230 hasConceptScore W3215767230C126322002 @default.
• W3215767230 hasConceptScore W3215767230C143998085 @default.
• W3215767230 hasConceptScore W3215767230C197934379 @default.
• W3215767230 hasConceptScore W3215767230C2777938653 @default.
• W3215767230 hasConceptScore W3215767230C2778461978 @default.
• W3215767230 hasConceptScore W3215767230C2778715236 @default.
• W3215767230 hasConceptScore W3215767230C2779878957 @default.
• W3215767230 hasConceptScore W3215767230C29730261 @default.
• W3215767230 hasConceptScore W3215767230C50382708 @default.
• W3215767230 hasConceptScore W3215767230C66339696 @default.
• W3215767230 hasConceptScore W3215767230C71924100 @default.
• W3215767230 hasConceptScore W3215767230C72563966 @default.
• W3215767230 hasIssue "Supplement 1" @default.
• W3215767230 hasLocation W32157672301 @default.
• W3215767230 hasOpenAccess W3215767230 @default.
• W3215767230 hasPrimaryLocation W32157672301 @default.
• W3215767230 hasRelatedWork W2160911489 @default.
• W3215767230 hasRelatedWork W2596040508 @default.
• W3215767230 hasRelatedWork W3074585435 @default.
• W3215767230 hasRelatedWork W3128509935 @default.
• W3215767230 hasRelatedWork W3184068580 @default.
• W3215767230 hasRelatedWork W4200103625 @default.
• W3215767230 hasRelatedWork W4200194158 @default.
• W3215767230 hasRelatedWork W4200585213 @default.
• W3215767230 hasRelatedWork W4226367882 @default.
• W3215767230 hasRelatedWork W4292448967 @default.
• W3215767230 hasVolume "138" @default.
• W3215767230 isParatext "false" @default.
• W3215767230 isRetracted "false" @default.
• W3215767230 magId "3215767230" @default.
• W3215767230 workType "article" @default.